Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network
Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network. // Clinical Lymphoma, Myeloma & Leukemia. – URL: https://www.sciencedirect.com/science/article/pii/S2152265026002168?dgcid=rss_sd_all
Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network. Clinical Lymphoma, Myeloma & Leukemia. https://www.sciencedirect.com/science/article/pii/S2152265026002168?dgcid=rss_sd_all
“Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network.” Clinical Lymphoma, Myeloma & Leukemia.
@article{article93539,
title = {Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network},
journal = {Clinical Lymphoma, Myeloma \& Leukemia},
url = {https://www.sciencedirect.com/science/article/pii/S2152265026002168?dgcid=rss_sd_all}
}